Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Simpson

Showing results (211-220 of 275) with videos related to

Pageof 28
Sort By:
Journal of Clinical and Experimental Neuropsychology|March 11, 2011
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological changeLucette A Cysique, Donald Franklin, Ian Abramson, et al.
Archives of Neurology|January 16, 2008
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous systemScott Letendre, Jennifer Marquie-Beck, Edmund Capparelli, et al.
Blood Advances|June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphomaConstantine S Tam, Stephen Opat, David Simpson, et al.
The Journal of Infectious Diseases|May 10, 2002
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267David A Wohl, Francesca T Aweeka, John Schmitz, et al.
AIDS (London, England)|February 1, 2019
Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effectsIgnacio Pérez-Valero, Ronald Ellis, Robert Heaton, et al.
AIDS and Behavior|June 23, 2012
Relationship of Medication Management Test-Revised (MMT-R) performance to neuropsychological functioning and antiretroviral adherence in adults with HIVDoyle E Patton, Steven Paul Woods, Donald Franklin, et al.
HIV Clinical Trials|April 20, 2010
Memantine for AIDS dementia complex: open-label report of ACTG 301Yu Zhao, Bradford A Navia, Christina M Marra, et al.
Leukemia & Lymphoma|January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemiaMasa Lasica, Abbey Willcox, Kate Burbury, et al.
Pathology|January 7, 2020
A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working GroupM Gohar Maqbool, Constantine S Tam, Ian M Morison, et al.
Leukemia & Lymphoma|January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studiesJan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
Pageof 28

Showing results (211-220 of 275) with videos related to

Sort By:
Pageof 28
Journal of Clinical and Experimental Neuropsychology|March 11, 2011
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological changeLucette A Cysique, Donald Franklin, Ian Abramson, et al.
Archives of Neurology|January 16, 2008
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous systemScott Letendre, Jennifer Marquie-Beck, Edmund Capparelli, et al.
Blood Advances|June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphomaConstantine S Tam, Stephen Opat, David Simpson, et al.
The Journal of Infectious Diseases|May 10, 2002
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267David A Wohl, Francesca T Aweeka, John Schmitz, et al.
AIDS (London, England)|February 1, 2019
Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effectsIgnacio Pérez-Valero, Ronald Ellis, Robert Heaton, et al.
AIDS and Behavior|June 23, 2012
Relationship of Medication Management Test-Revised (MMT-R) performance to neuropsychological functioning and antiretroviral adherence in adults with HIVDoyle E Patton, Steven Paul Woods, Donald Franklin, et al.
HIV Clinical Trials|April 20, 2010
Memantine for AIDS dementia complex: open-label report of ACTG 301Yu Zhao, Bradford A Navia, Christina M Marra, et al.
Leukemia & Lymphoma|January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemiaMasa Lasica, Abbey Willcox, Kate Burbury, et al.
Pathology|January 7, 2020
A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working GroupM Gohar Maqbool, Constantine S Tam, Ian M Morison, et al.
Leukemia & Lymphoma|January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studiesJan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
Pageof 28